Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | HTR2C | P28335 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.42 |
| ▸ | GPR3 | P46089 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | HTR3A | P46098 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.41 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.41 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.41 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.41 |
| ▸ | HTR3B | O95264 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8270650 | 0.81 | BRD4 (0.32) | — | |
| SCHEMBL5809427 | 0.81 | AGTR1 (0.39) | HTR2C | |
| SCHEMBL984 | 0.80 | HTR2A (0.54) | HTR2AHTR2CKDM4EALOX15MAPK1 | |
| SCHEMBL7428637 | 0.74 | HTR2A (0.51) | HTR2AHTR2CKDM4EALOX15MAPK1 | |
| SCHEMBL1146660 | 0.74 | HTR2A (0.51) | HTR2AHTR2CKDM4EALOX15MAPK1 | |
| SCHEMBL30223533 | 0.74 | HTR2A (0.51) | HTR2AHTR2CKDM4EALOX15MAPK1 | |
| SCHEMBL13157509 | 0.73 | KCNH2 (0.54) | HTR2AHTR2CKDM4EALOX15MAPK1 | |
| SCHEMBL918 | 0.73 | BRD4 (0.57) | HTR2AHTR2CKDM4EALOX15MAPK1 | |
| SCHEMBL13157508 | 0.72 | KCNH2 (0.55) | HTR2AHTR2CKDM4EALOX15MAPK1 | |
| SCHEMBL19159482 | 0.71 | HTR2A (0.47) | HTR2AHTR2CKDM4EALOX15MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7696356-B2 | Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one and ondansetron therefrom | TARO PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2010-04-13 | — | — | US | claimed |
| EP-1828141-A4 | A ONE-POT PROCESS FOR THE PREPARATION OF ANTIEMETIC AGENT, 1,2,3,9-TETRAHYDRO-9-METHYL-3[(2-METHYL)-1H-IMIDAZOLE-1-YL)METHYL]-4H-CARBAZOL-4-O | IPCA LAB LTD (IN) | 2009-04-01 | — | — | EP | claimed |
| US-20080009635-A1 | One-Pot Process for the Preparation of Antiemetic Agent, 1,2,3,9-Tetrahydro-9-Methyl-3[(2-Methyl)-1H-Imidazole-1-Yl)Methyl]-4H-Carbazol-4-O | IPCA LABORATORIES LIMITED (IN) | 2008-01-10 | — | — | US | claimed |
| EP-1828141-A1 | A ONE-POT PROCESS FOR THE PREPARATION OF ANTIEMETIC AGENT, 1,2,3,9-TETRAHYDRO-9-METHYL-3[(2-METHYL)-1H-IMIDAZOLE-1-YL)METHYL]-4H-CARBAZOL-4-O | IPCA Laboratories Limited (IN) | 2007-09-05 | — | — | EP | claimed |
| US-20060252942-A1 | Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-YL)methyl]-4H-carbazol-4-one | MOLNAR SANDOR | 2006-11-09 | — | — | US | claimed |
| WO-2006046253-A1 | A ONE-POT PROCESS FOR THE PREPARATION OF ANTIEMETIC AGENT, 1,2,3,9-TETRAHYDRO-9-METHYL-3[(2-METHYL)-1H-IMIDAZOLE-1-YL)METHYL]-4H-CARBAZOL-4-O | IPCA LABORATORIES LIMITED (IN) | 2006-05-04 | — | — | WO | claimed |
| US-20060041004-A1 | Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one and ondansetron therefrom | TARO PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2006-02-23 | — | — | US | claimed |
| WO-2006018846-A2 | PROCESS FOR PREPARING 1,2,3,9-TETRAHYDRO-9-METHYL-3-METHYLENE-4H- CARBAZOL-4-ONE AND ONDANSETRON THEREFROM | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-02-23 | — | — | WO | claimed |
| US-20050020655-A1 | Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[2-methyl-1H-imidazol-1-YL)methyl]-4H-carbazol-4-one | TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG (HU) | 2005-01-27 | — | — | US | claimed |
| EP-1499623-A1 | PROCESS FOR PREPARING 1,2,3,9-TETRAHYDRO-9-METHYL-3-[(2-METHYL-1H-IMIDAZOL-1-YL)METHYL]-4H-CARBAZOL-4-ONE | BIOGAL GYOGYSZERGYAR RT. (HU) | 2005-01-26 | — | — | EP | claimed |
| WO-2003093281-A1 | PROCESS FOR PREPARING 1,2,3,9-TETRAHYDRO-9-METHYL-3-[(2-METHYL-1H-IMIDAZOL-1-YL)METHYL]-4H-CARBAZOL-4-ONE | BIOGAL GYOGYSZERGYAR RT. (HU) | 2003-11-13 | — | — | WO | claimed |
| US-7696356-B2 | Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one and ondansetron therefrom | TARO PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2010-04-13 | — | — | US | disclosed |
| US-7696356-B2 | Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one and ondansetron therefrom | TARO PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2010-04-13 | — | — | US | disclosed |
| US-7696356-B2 | Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one and ondansetron therefrom | TARO PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2010-04-13 | — | — | US | disclosed |
| US-7696356-B2 | Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one and ondansetron therefrom | TARO PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2010-04-13 | — | — | US | disclosed |
| EP-0595111-B1 | Carbazolone derivatives and process for preparing the same | RICHTER GEDEON VEGYESZET (HU) | 1997-09-10 | — | — | EP | disclosed |
| US-5478949-A | Reacting the starting carbazolone with dialkyl oxalate, then formaldehyde and 2-methylimidazole | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1995-12-26 | — | — | US | disclosed |
| US-5416221-A | ONDANSETRON INTERMEDIATES | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1995-05-16 | — | — | US | disclosed |
| EP-0595111-A1 | Carbazolone derivatives and process for preparing the same | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1994-05-04 | — | — | EP | disclosed |
| US-4695578-A | 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances | GLAXO GROUP LIMITED (GB) | 1987-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020655-A1 | Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[2-methyl-1H-imidazol-1-YL)methyl]-4H-carbazol-4-one | CYP3A4, HTR4, TPH1 | HTR2A 64/4885HTR2C 7/4885KDM4E 475/4885 |
| US-20060041004-A1 | Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one and ondansetron therefrom | HTR3A, ADORA3, HTR4 | HTR2A 22/4885HTR2C 10/4885KDM4E 833/4885 |
| US-20060252942-A1 | Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-YL)methyl]-4H-carbazol-4-one | SI, CYP3A4, CYP2C19 | HTR2A 76/4885HTR2C 10/4885KDM4E 797/4885 |
| US-20080009635-A1 | One-Pot Process for the Preparation of Antiemetic Agent, 1,2,3,9-Tetrahydro-9-Methyl-3[(2-Methyl)-1H-Imidazole-1-Yl)Methyl]-4H-Carbazol-4-O | CRHR2, HCRTR2, HTR1D | HTR2A 14/4885HTR2C 7/4885KDM4E 1490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.